


Key facts

	Females	Males	Total
Number of new cases per year	207	69.0	276
Incidence rate (cases per 100,000 per year)	8.4	2.8	-
Cumulative lifetime risk of diagnosis (to age 74)	1 in 149	1 in 435	-
Percentage of all invasive cancers *	2%	0.6%	1.2%
Ranking among most common cancers *	13 th	19 th	19 th
Number of deaths per year	18.0	10.0	28.0
Mortality rate (deaths per 100,000 per year)	0.6	0.4	-
Cumulative lifetime risk of death (to age 74)	1 in 2,500	1 in 3,333	-
Percentage of all cancer deaths	<1%	<1%	<1%
Ranking among most common invasive cancer deaths	19 th	18 th	21 st
Number of people with this cancer still alive, end 2015 #	1,919	565	2,484
Number alive per 100,000	84.0	25.0	54.0

*invasive cancers only, excluding non-melanoma skin cancer


diagnosed since 1994

Cases mapped by county



Annual average number of cases, 2005-2015: colours indicate higher or lower than expected based on national rates


Age profile at diagnosis and death




Top risk factors

- Being between 25 and 65 years old
 - Being female
- Being exposed to radiation to the head and neck as an infant or child or being exposed to radiation from an atomic bomb
 - History of goiter (enlarged thyroid)
- Family history of thyroid disease or thyroid cancer
- Certain genetic conditions such as familial medullary thyroid cancer (FMTC), multiple endocrine neoplasia type 2A syndrome (MEN2A), and multiple endocrine neoplasia type 2B syndrome (MEN2B)
 - Being Asian

Trend in incidence and mortality



Stage at diagnosis



APC# Incidence: Males (94-15) 5.9%; Females (94-08) 6.1% (08-11) 21.8% (11-15)-0.4%
 Mortality: Males (94-15) 0.1%; Females (94-06) -5.5%, (06-15) 3.4%
 # Annual Percentage Change

Treatment within 1 year

99%
pathologically
diagnosed

2%
Chemotherapy

47%
Radiotherapy

87%
Surgery

% of all cases diagnosed 2013-2015

5 year net survival

Diagnosed	Net survival (age standardised)	95% confidence interval
1994-1998	70.7%	65.7-75.7%
1999-2003	72.3%	67.6-77.0%
2004-2008	82.1%	78.5-85.7%
2009-2013	86.2%	83.1-89.2%

*10 year net survival (hybrid analysis):

78.4% (73.1-83.8%)